Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 17, 2009Cancer

Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

CHCelestia S. HiganoPSPaul F. SchellhammerESEric J. Small

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Higano et al. (2009) studied this question.

synapsesocial.com/papers/6a6e20aa35aa2c282ce026a2https://doi.org/10.1002/cncr.24429
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer1996 · 48 citations
  2. 2Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer2006 · 1,105 citations
  3. 3Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial2004 · 191 citations
  4. 4The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer1995 · 173 citations
  5. 5A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma2002 · 1,663 citations